logo

ARCT

Arcturus Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ARCT fundamentals

Arcturus Therapeutics (ARCT) released its earnings on Nov 10, 2025: revenue was 17.15M (YoY -58.85%), beat estimates; EPS was -0.49 (YoY -88.46%), beat estimates.
Revenue / YoY
17.15M
-58.85%
EPS / YoY
-0.49
-88.46%
Report date
Nov 10, 2025
ARCT Earnings Call Summary for Q3,2025
  • CF program momentum: 30% mucus plug reduction in Phase II trial, with 20-patient enrollment targeted.
  • Financial stability: $237M cash runway supports 2026 trials.
  • Collaboration continuity: Meiji Pharma sales in Japan.
EPS
Revenue

Revenue & Expenses

ARCT has released its 2025 Q3 earnings report, with revenue of 17.15M, reflecting a YoY change of -58.84%, and net profit of -13.45M, showing a YoY change of -94.81%. The Sankey diagram below clearly presents ARCT's revenue sources and cost distribution.

Key Indicators

Arcturus Therapeutics (ARCT) key financial stats and ratios, covering profitability, financial health, and leverage.
Arcturus Therapeutics (ARCT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Arcturus Therapeutics (ARCT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Arcturus Therapeutics (ARCT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Arcturus Therapeutics (ARCT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Arcturus Therapeutics (ARCT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield